Literature DB >> 31076855

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.

Umran Kucukgoz Gulec1, Emine Kilic Bagir2, Semra Paydas3, Ahmet Baris Guzel4, Derya Gumurdulu2, Mehmet Ali Vardar4.   

Abstract

PURPOSE: The aim of this study was to evaluate prognostic importance of programmed death-1 (PD-1) and/ or programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. Study design Formalin-fixed, paraffin-embedded tissue samples from 53 cases with type 2 endometrial cancer were analyzed. One-third of our cases had serous adenocarcinoma (32%), 11 had clear cell (21%) and 25 had mixed-type adenocarcinoma (47%). PD-1 and PD-L1 expressions in tumor tissue and microenvironment were detected by immunohistochemistry. Clinical and pathological characteristics including age, stage, initial symptom, surgical procedure, myometrial invasion, lymphovascular space invasion (LVSI), lymph node invasion, adjuvant therapy, and survival were reviewed. The Kaplan-Meier and Cox proportional hazards models were used to evaluate the prognostic factors.
RESULTS: PD-1 expression in tumor tissue and microenvironment was detected in 22 (42%) and 28 (53%) cases, respectively. PD-L1 expression was detected in tumor and microenvironment in 8 (15%) and in 15 cases (28%), respectively. Expression of PD-1 and PD-L1 expressions in tumor area was associated with shorter survival (p = 0.006 and 0.001, respectively) but PD-1 and PD-L1 expressions in microenvironment were not found to be related with survival. PD-1 (p = 0.006) and PD-L1 expressions (p = 0.001) in addition to LVSI (p = 0.005), myometrial invasion (p = 0.015), lymph node involvement (p = 0.019), and suboptimal cytoreduction (p = 0.042), were found to be associated with poor prognostic indicators. PD-1 and PD-L1 expressions in tumor and lymph node involvement were determined as independent prognostic factors.
CONCLUSION: PD-1 and PD-L1 expressions in type 2 endometrial cancers were found to be poor prognostic indicators.

Entities:  

Keywords:  Prognostic factors; Programmed death-1 (PD-1); Programmed death-ligand 1 (PD-L1); Type 2 endometrial cancer; Uterine clear cell carcinoma; Uterine mixed type adenocarcinoma; Uterine serous carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31076855     DOI: 10.1007/s00404-019-05180-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Endometrial Tumour Microenvironment.

Authors:  Carlos Casas-Arozamena; Miguel Abal
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.

Authors:  Ling Lu; Yonghong Li; Rong Luo; Junhui Xu; Jie Feng; Mingqiang Wang
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

3.  Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.

Authors:  Chen Zhang; Qing Yang
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

4.  Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis.

Authors:  Yuan Cheng; Xiaobo Zhang; Zhiqi Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

5.  RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.

Authors:  Rong Geng; Yuhua Zheng; Lijie Zhao; Xiaobin Huang; Rong Qiang; Rujian Zhang; Xiaoling Guo; Ruiman Li
Journal:  Front Genet       Date:  2020-11-26       Impact factor: 4.599

6.  Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.

Authors:  Jinhui Liu; Rui Geng; Sheng Yang; Fang Shao; Zihang Zhong; Min Yang; Senmiao Ni; Lixin Cai; Jianling Bai
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

7.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.

Authors:  Tao Zhang; Qin Liu; Yingfan Zhu; Songfa Zhang; Qiaohua Peng; Amanda Louise Strickland; Wenxin Zheng; Feng Zhou
Journal:  Cancer Manag Res       Date:  2021-12-14       Impact factor: 3.989

Review 8.  Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.

Authors:  Gian Franco Zannoni; Emma Bragantini; Francesca Castiglione; Matteo Fassan; Giancarlo Troncone; Frediano Inzani; Anna Pesci; Angela Santoro; Filippo Fraggetta
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.